touchONCOLOGY joins Professor Myung-Ju Ahn (Samsung Medical Center, Seoul, South Korea) at WCLC 2021 to discuss the AURA3 trial of osimertinib as a treatment for EGFR-mutant non-small cell lung cancer.
Abstract: FP16.03
ClinicalTrials.gov Identifier: NCT02151981
Questions
1. What are the strengths and limitations of osimertinib as a treatment for EGFR-mutant non-small cell lung cancer? (00:17-01:13)
2. Could you give us a brief overview of the AURA3 clinical trial and its findings? (01:13-02:03)
3. What clinical evidence supports the use of circulating tumour DNA assay as a predictor of clinical response to osimetinib? (02:03-02:47)
4. Could you tell us a little about your analysis and its findings? (02:47-06:27)
5. What is the potential impact of these findings on clinical practice, and what further studies are needed? (06:27-07:45)
Disclosures: Myung-Ju Ahn has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 WCLC Annual Meeting.
